GSK tries to steady the ship as Arexvy sales plummet in wake of CDC guidance changes

To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. For the company’s closely watched respiratory syncytial virus (RSV) vaccine Arexvy, those challenges led to drastically reduced sales.

After a stunning ascension to blockbuster status in its RSV debut last year, GSK’s Arexvy has quickly fallen back to earth this year. During the third quarter, the shot’s sales plummeted 74% year over year to 188 million pounds sterling ($244 million).